PMC4533482_01
A: T2-weighted axial magnetic resonance (MR) imaging demonstrating no apparent intracranial abnormalities. B: MR sagittal scout imaging demonstrating no apparent abnormalities.
nmc-54-327-g1.jpg
PMC4533482_01_nmc-54-327-g1.jpg
F1
He received a brain check-up at another hospital in November 2007, and no intracranial abnormalities were detected (Fig. 1).
A: Gadolinium-enhanced T1-weighted coronal magnetic resonance imaging (MRI) demonstrating an extramedullary homogenously enhanced tumor at the parasagittal region expanding into the falx and skull bone. B: Gadolinium-enhanced T1-weighted sagittal MRI.
nmc-54-327-g2.jpg
PMC4533482_01_nmc-54-327-g2.jpg
F2
T1-weighted images (WI) and high-intense on T2WI, and was homogeneously enhanced after intravenous injection of contrast materials. The diameter of the tumor reached 5 cm (Fig. 2).
Photomicrographs of the resected tumor. A: Whorl arrangements are seen in places. Necrosis is not identified. Hematoxylin and eosin (H&E) staining, original magnification x200. B: Tumor cells are largely uniform and have oval nuclei. Mitoses are not identified. H&E staining, original magnification x400. C: Molecular immunology borstel (MIB)-1 staining index is 5%. Immunohistochemical stain for Ki-67, original magnification x400. D: The cytoplasm of tumor cells is immunopositive for the LH-RH receptor. Immunohistochemical stain for the LH-RH receptor, original magnification x400. LH-RH: luteinizing hormone-releasing hormone.
nmc-54-327-g3.jpg
PMC4533482_01_nmc-54-327-g3.jpg
F3
Cytoplasmic immunoreactivity for the luteinizing hormone-releasing hormone (LH-RH) receptor was detected (Fig. 3).
No recurrent tumor is identified 16 months after the operation. A: Gadolinium-enhanced T1-weighted coronal magnetic resonance imaging (MRI). B: Gadolinium-enhanced T1-weighted sagittal MRI.
nmc-54-327-g4.jpg
PMC4533482_01_nmc-54-327-g4.jpg
F4
On July 11, 2012, sixteen months after the operation, brain MRI demonstrated no tumor recurrence (Fig. 4).